2-D Fluorescence Difference Gel Electrophoresis (2-D DIGE) technology is covered by US patent numbers 6,043,025, 6,127,134 and 6,426,190 and equivalent patents and patent applications in other countries and exclusively licensed from Carnegie Mellon University.  CyDye: this product or portions thereof is manufactured under an exclusive license from Carnegie Mellon University under US patent numbers 5,569,587, 5,627,027 and equivalent patents in other countries. The purchase of CyDye DIGE Fluors includes a limited license to use the CyDye DIGE Fluors for internal research and development, but not for any commercial purposes. A license to use the CyDye DIGE Fluors for commercial purposes is subject to a separate license agreement with GE Healthcare.

7-deaza-dGTP is sold pursuant to a license and is covered by US patent number 5,480,980 issued by Boehringer Mannheim GmbH.

ÄKTA oligopilot and OligoPilot 400 is covered by US patent number 5,807,525 and equivalent patents and patent applications in other countries. Post-synthesis procedures for selective deprotection of oligonucleotides on solid supports is covered by US patent number 6,887,990 and equivalent patents and patent applications in other countries, and a license thereto is only given when synthesis of oligonucleotides is performed on GE Healthcare instruments. No other license is granted to the purchaser either directly or by implication, estoppel or otherwise. 

The use of ÄKTAready High Flow Kit and Low Flow Kit may require a license under the following US patents and their equivalents in other countries: US patent numbers 6,712,963 and 7,052,603 (assignee: SciLog, Inc.). A free, non-transferable license limited to using these products under above mentioned patents accompanies the purchase of the product from any GE Healthcare company and its licensed distributors.

This product is protected by patent numbers US 5,939,257 and EP 770678 owned by GE Healthcare Bio-Sciences Corp. and equivalent patents and patent applications in other countries.

The use of this product in a binding assay is the subject of patent numbers US 6,900,019 and EP 0863402 and equivalent patents and patent applications in other countries in the name of GE Healthcare UK Limited.

The use of this product in a binding assay is the subject of patent numbers US 6,900,019 and EP 0863402 and equivalent patents and patent applications in other countries in the name of GE Healthcare UK Limited.

These products are developed in collaboration with FUJI CHEMICAL INDUSTRIES, Ltd.(Japan).

These products are manufactured by FUJI CHEMICAL INDUSTRIES, Ltd. (Japan).

The use of this product in a binding assay is the subject of patent numbers US 6,900,019 and EP 0863402 and equivalent patents and patent applications in other countries in the name of GE Healthcare UK Limited.

Separating Miraculin with this product is subject to US patent number 5,886,155. Licenses are available from BioResources International, Inc., of Somerset, N.J., U.S.A.

GE Healthcare Cardiomyocytes are sold under licence from Geron Corporation and Wisconsin Alumni Research Foundation under US patent and publication numbers: 7,425,448, 7,851,167, 6,800,480, 5,843,780, 6,200,806, 7,029,913, 7,582,479, 7,413,902, 7,297,539, 2009/0047739 and 2007/0010012 and equivalent patent and patent applications in other countries.

CDP-Star is a trademark of Tropix Inc and protected under one or more US patent numbers 5,851,771, 5,538,847, 5,326,882 and 5,145,772 owned by Tropix Inc.

This release of DeCyder version 2 (software) is provided by GE Healthcare to the customer under a non-exclusive license and is subject to terms and conditions set out in the 2-D Differential Gel Electrophoresis Technology Access Agreement.  Customer has no rights to copy or duplicate or amend the Software without the prior written approval of GE Healthcare.

This version of the DeCyder SA module has been developed by the Swiss Institute of Bioinformatics in collaboration with GeneBio and GE Healthcare.

Deep Purple Total Protein Stain is exclusively licensed to GE Healthcare from Fluorotechnics Pty Ltd.
Deep Purple Total Protein Stain may only be used for applications in life science research.
Deep Purple is covered under a granted patent in New Zealand entitled “Fluorescent Compounds", patent number 522291 and equivalent patents and patent applications in other countries.

This product is sold under license from Johnson & Boley Holdings, LLC under US patent number 6,679,529.

ECF Substrate is manufactured for GE Healthcare by Europa BioProducts.  This component is covered by US patent number 5,424,440 and EP 424,465 B1 and is sold under license from Promega.

ECL Advance contains Lumigen TMA-6 substrate and is sold under license from Lumigen, Inc.

TMA-6 substrate was developed by Lumigen, Inc. and is distributed by GE Healthcare for western blotting under license from Lumigen, Inc. This component is covered by US patent numbers 5,922,558, 6,696,569, 6,858,733 and 7,560,556 and equivalent patents and patent applications in other countries and is sold under license from Lumigen, Inc.

Note: Lumigen’s trademark to be included in inserts for Kits, in sales literature for Kits and Substrate, and on labels for bottles of Substrate.

ECL Plus contains Lumigen PS4 substrate and is sold under license from Lumigen, Inc.

ECL Plus Western Blotting Detection Reagents are manufactured for GE Healthcare by Lumigen, Inc. The PS3 substrate is covered by US patent numbers 5,491,072, 5,593,845 and 5,750,698 and equivalent patents and patent applications in other countries and is sold under license from Lumigen, Inc.

Note: Lumigen’s trademark to be included in inserts for Kits, in sales literature for Kits and Substrate, and on labels for bottles of Substrate.

This product or portions thereof is manufactured and sold under license from Cyanagen Srl and is subject of US patent application number 2008/176251, US Patent 7,803,573, and Italian application number TO2010A000580, together with other equivalent granted patents and patent applications in other countries.

Exonuclease I/Shrimp Alkaline Phosphatase method of use is covered by one or more of the following US patent numbers: 5,756,285 and 5,741,676 in the name of GE Healthcare Bio-Sciences Corp.

“MabSelect SuRe Ligand Restricted License” and “Cys-rProtein A Ligand Restricted License” are protected by the following patents and equivalent patents and patent applications in other countries: US 6,399,750 and EP 1123389. A free, non-transferable limited license to use this product for internal analytical purposes only accompanies the purchase of the product from a GE Healthcare company and its licensed distributors. Any other use will require a separate license from a GE Healthcare company.

Gene Images hybridization buffer is covered by EP 610212 B1 and equivalent patents and patent applications in other countries owned by GE Healthcare Bio-Sciences and covered by a non-exclusive license to US patent number 5,853,986 in the name of Becton Dickinson and Company.

GFP and Emerald FP Products:

This product is sold under license from Fisher BioImage ApS (formerly BioImage A/S) under patent numbers US 6,172,188, US 6,818,443, US 5,958,713, CA 2232727, EP 0815257, EP 851874, JP 3535177 and equivalent patents and patent applications in other countries.

This product is sold under license from Invitrogen IP Holdings Inc (formerly Vertex Pharmaceuticals (San Diego) LLC, formerly Aurora Biosciences Corporation) under patent numbers US 5,625,048, US 5,777,079, US 5,804,387, US 5,968,738, US 5,994,077, US 6,054,321, US 6,066,476, US 6,077,707, US 6,090,919, US 6,124,128, US 6,319,669, US 6,403,374, EP 0804457, JP 3283523 and equivalent patents and patent applications in other countries.

This product is sold under license from Columbia University under patent numbers US 5,491,084 and 6,146,826.

Note: An exception is for products containing mutations at position 222 such as the triple GFP mutant (F64L, E222G, S175G) where the Invitrogen IP Holdings does not apply. For example, MAPKAP-k2, Rac-1 and PLC-PH Domain products.

For assays involving a mutation at position 222 then an additional line for the Fisher BioImage ApS statement is required: This product is sold under license from Fisher BioImage ApS (formerly BioImage A/S) under patent number US 7,001,986 and equivalent patents and patent applications in other countries.

For assays involving a humanized codon, an additional line is required: This product is sold under license from University of Florida under patent numbers US 5,968,750, US 5,874,304, US 5,795,737, US 6,020,192 and equivalent patents and patent applications in other countries.

For assays containing a Triple Mutant, an additional line is required:

This product is the subject of patent numbers US 6,919,186, US 7,091,317 and EP 1381625 and equivalent patents and patent applications in other countries in the name of GE Healthcare Limited.

For assays involving a CMV promoter, an additional line is required:

The CMV promoter is covered under patent number US 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA52242, USA.

For assays developed by Fisher BioImage ApS (formerly BioImage A/S), such as the Akt, SMAD2, STAT3, NFAT-C2, MAPKAP-k2, Rac-1, PLC- PH Domain products:

This product was developed in collaboration with Fisher BioImage ApS (formerly BioImage A/S).

For assays involving Redistribution:

This product is sold under license from Fisher BioImage ApS (formerly BioImage A/S) under patent numbers US 6,518,021 and EP 0986753 and equivalent patents and patent applications in other countries.

For assays involving a G2M Cell Cycle Phase Marker:

The G2M Cell Cycle Phase Marker Assay is the subject of patent applications AU 2002326036, CA 2461133, EP 02760417.2, IL 160908, JP 2003-534582 and US 10/491762 in the name of GE Healthcare UK Limited and Cancer Research Campaign Technology.

For assays involving a G1S Cell Cycle Phase Marker:

The G1S Cell Cycle Phase Marker assay is the subject of international patent application numbers PCT/GB2005/002876, PCT/GB2005/002884 and PCT/GB2005/002890 in the name of GE Healthcare UK Limited and Vanderbilt University. 

For assays involving an FYVE domain:

This product is sold under license from Cedars Sinai Medical Centre under patent number US 6,376,174 and equivalent patents and patent applications in other countries.

For assays involving an STAT3:

This product is sold under license from Osaka University under patent numbers US 5,719,042 and US 5,844,082 and equivalent patents and patent applications in other countries.

This product was developed in collaboration with Fisher BioImage ApS (formerly BioImage A/S).

For assays involving an NFAT-c1:

This product is sold under license from Leland Stanford Junior University under patent numbers US 5,837,840, US 5,989,810, US 6,171,781, US 6,197,925, US 6,312,899, US 6,352,830, US 6,388,052, US 6,150,099, EP 0722452 and equivalent patents and patent applications in other countries.

For assays involving an NFAT-RE:

This product is sold under license from Leland Stanford Junior University under patent numbers US 5,837,840, US 5,989,810, US 6,171,781, US6,197,925, US 6,312,899, US 6,352,830, US 6,388,052, US 6,150,099, EP 0722452 and equivalent patents and patent applications in other countries.

For assays involving an MADR2/SMAD2:

This product is sold under license from HSC Research and Development Limited Partnership under patent number US 6,017,755 and equivalent patents and patent applications in other countries.

This product was developed in collaboration with Fisher BioImage ApS (formerly BioImage A/S).

For assays involving the PLC – PH Domain:

For customers wishing to use the assay for screening for potential therapeutic agents, attention is drawn to the existence of US patent number 6,054,280 ‘Methods for Diagnosis and Treatment of PH Domain Signal Transaction Disorders’, issued 25 April 2000 and assigned to Sugen Inc., CA, USA.

This product was developed in collaboration with Fisher BioImage ApS (formerly BioImage A/S).

A license for commercial use of GST Gene Fusion Vectors under US patent 5,654,176 and equivalent patents and patent applications in other countries must be obtained from Millipore Corp (formerly Chemicon International Inc).

Purchase of this product includes an immunity from suit under patents specified in the product insert to use only the amount purchased for the purchaser’s own internal research.  No other patent rights are conveyed expressly, by implication, or by estoppel.  Further information on purchasing licenses may be obtained by contacting the Director of Licensing, Applied Biosystems, 850 Lincoln Centre, Drive, Forest City, CA 94404, USA.

This product is sold under licensing arrangements with Stratagene.  The purchase price of this product includes limited, nontransferable rights under U.S. Patent Nos. 5,449,603, 5,605,824, 5,646,019, 5,773,257 owned by Stratagene to use only this amount of the product to practice the claims in said patents solely for activities of end users within the field of life science research.  Further licensing information may be obtained by contacting the Business Development Department, Stratagene California, 11011 North Torrey Pines Road, La Jolla, California 92307.

This product is sold under license from USB Corporation, Cleveland, Ohio, for use as described in the accompanying materials.  Further licensing information may be obtained by contacting USB Corporation, 26111 Miles Road, Cleveland, Ohio 44142.  Patent Pending.  All rights reserved.

Purchase of this product includes an immunity from suit under patents specified in the product insert to use only the amount purchased for the purchaser’s own internal research.  No other patent rights are conveyed expressly, by implication, or by estoppel.  Further information on purchasing licenses may be obtained by contacting the Director of Licensing, Applied Biosystems, 850 Lincoln Centre, Drive, Forest City, CA 94404, USA.

(Histidine-tagged protein purification, Bioprocess products)

US patent numbers 5,284,933 and 5,310,663, and equivalent patents and patent applications in other countries (assignee: Hoffman La Roche, Inc) relate to the purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues (commonly known as the histidine-tag technology).

Any customer that wishes to use Chelating Sepharose Fast Flow, Ni Sepharose 6 Fast Flow or IMAC Sepharose 6 Fast Flow for non-research/commercial applications under these patents is requested to contact Hoffman-La Roche AG, Corporate licensing, attention Dr Andreas Maurer, CH-4070 Basel, Switzerland, telephone +41 61 687 2548, fax +41 61 687 2113, for the purpose of obtaining a license.

(Histidine-tagged protein purification, Lab products)

Purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues may require a license under US patent numbers 5,284,933 and 5,310,663, and equivalent patents and patent applications in other countries (assignee: Hoffman La Roche, Inc).

These products are sold under a license from Sigma-Aldrich under patent number EP 1277616 (Metal chelating compositions) and equivalent patents and patent applications in other countries.  

This version of ImageMaster has been developed by the Swiss Institute of Bioinformatics in collaboration with GeneBio and integrates the Melanie software.

This version of ImageMaster has been developed by the Swiss Institute of Bioinformatics in collaboration with GeneBio and GE Healthcare.

The IN Cell Analyzer system and the In Cell Investigator software are sold under use license from Cellomics Inc. under US patent numbers: 5,989,835, 6,365,367, 6,416,959,  6,573,039, 6,620,591, 6,671,624, 6,716,588, 6,727,071, 6,759,206, 6,875,578, 6,902,883, 6,917,884, 6,970,789, 6,986,993, 7,060,445, 7,085,765, 7,117,098, 7,160,687, 7,235,373, 7,476,510 ; Canadian patent numbers CA 2282658, 2328194, 2362117, 2381344; Australian patent number AU 730100; European patent numbers EP 0983498, 1095277, 1155304, 1203214, 1348124, 1368689; Japanese patent numbers JP 3466568, 3576491, 3683591, 4011936 and equivalent patents and patent applications in other countries.

KappaSelect incorporates BAC BV's proprietary ligand technology, which has been exclusively licensed to GE Healthcare for affinity separation. Other uses of this product may require a separate license from BAC BV, Huizerstraatweg 28, 1411 GP Naarden, The Netherlands.

Notice to Purchaser: Limited License

The MegaBACE instrument is a confocal scanning system licensed under US patent number 5,274,240 and equivalent patents and patent applications in other countries, including any continuations, continuations-in-part, and subdivisions and the like.

The instrument is also an Authorized DNA Sequencer.  It is authorized under one or more US patent number 5,366,860, and equivalent patents and patent applications in other countries. The purchase of this instrument includes limited, non-exclusive rights under the subject patents to use this instrument for sequencing and fragment length analysis when used with authorized reagents.  The use of this instrument with authorized reagents provides a limited license to perform DNA sequencing and fragment length analysis in accordance with the label rights accompanying such reagents.  Purchase of this instrument does not itself convey to the purchaser a complete license to perform DNA sequencing and fragment length analysis under the subject patents.  Authorized reagents may be obtained from licensed vendors, or reagents may be authorized  under separate license arrangements from PE Applied Biosystems. The above patent rights are granted solely, for research and other uses that are not unlawful.  No other licenses are granted expressly, impliedly, or by estoppel.
Further information on purchasing licenses to perform DNA sequencing and fragment length analysis may be obtained by contacting the Director of Licensing at Applied Biosystems, 850 Lincoln Center Drive, Foster City, California 94404.

Applied Biosystems does not guarantee the performance of this instrument. GE Healthcare is a licensed vendor for authorized reagents.

GE Healthcare is licensed as a vendor for authorized sequencing and fragment analysis instruments.

This kit is sold pursuant to Authorization from PE Applied Biosystems under one or more of the following US patent numbers 5,242,796; 5,306,618; 5,332,666; and 5,366,860, and equivalent patents and patent applications in other countries. The purchase of this kit includes limited non-transferable rights (without the right to resell, repackage, or further sublicense) under such patent rights to use this kit for DNA sequencing or fragment analysis, solely when used in conjunction with an automated instrument for DNA sequencing or analysis which have been authorized for such use by Applied Biosystems, or for manual sequencing.  Purchase of this product does not itself convey to the purchaser a complete license or right to perform automated DNA sequence and fragment analysis under the subject patents.  No other license is hereby granted for use of this kit in any other automated sequence analysis instrument.  The rights granted hereunder are solely for research and other used that are not unlawful.  No other license is granted expressly, impliedly, or by estoppel.

Further information on purchasing licenses to perform DNA sequence and fragment analysis may be obtained by contacting the Director of Licensing at Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404.

GE Healthcare is licensed as a vendor for authorized sequencing and fragment analysis instruments.

NTR products are sold for use with CytoCy5S in in vitro gene reporter assays only. Use in any in vivo application in humans or animals is strictly prohibited.
The use of this product in an NTR gene reporter assay is the subject of patent number EP 1252520 and equivalent patents and patent applications in other countries. This product is developed and sold under license from Cancer Research Campaign Limited and Proacta Inc. under patent numbers US 5,633,158, US 5,780,585, US 5,977,065, AU 681337, AU 725236 and equivalent patents and patent applications in other countries.

OligoProcess is covered by US patent numbers 5,807,525 and 5,641,459, and equivalent patents and patent applications in other countries. Post-synthesis procedures for selective deprotection of oligonucleotides on solid supports is covered by US patent number 6,887,990 and equivalent patents and patent applications in other countries, and a license thereto is only given when synthesis of oligonucleotides is performed on GE Healthcare instruments. No other license is granted to the purchaser either directly or by implication, estoppel or otherwise.

Percoll PLUS is protected by the following patents and equivalent patents and patent applications in other countries, which are licensed to GE Healthcare from Dendreon Corporation: US patent number 5,789,148, US patent number 6,015,843 and European patent number 1,047,635. A free, non-transferable license to use this product for density gradient separation purposes under the above mentioned patent rights accompanies the purchase of the product from a GE Healthcare company and its licensed distributors, but any use of Percoll PLUS or any other organosilanized colloidal silica particle-based separation media to enrich, purge or isolate cells for active immunotherapy for oncology applications shall be excluded from such license.

pGEX Vectors are to be used for scientific investigation and research and for no other purpose whatsoever and a license for commercial use of the licensed products and the processes claimed in US patent 5,654,176 and equivalent patents and patent applications in other countries must be negotiated directly with Millipore Corp (formerly Chemicon International Inc) by the purchaser prior to such use.

Phi 29 DNA polymerase and its use for DNA synthesis is covered by US patent numbers 5,854,033, 5,198,543 and 5,576,204.

The Plasminogen Removal Gel is subject to EP 1390485 and its foreign equivalents, and other intellectual property rights owned by OMRIX BIOPHARMACEUTICALS S.A, Belgium (“OMRIX”). Any customer wishing to use Plasminogen Removal Gel for any purpose falling under any valid claims of the said patent rights other than for research purposes needs prior to such use to (a) contact OMRIX directly and (b) sign a license agreement with OMRIX.

Primer Support 200 is covered by US patent number 6,335,438 and equivalent patents and patent applications in other countries.

Purchase of this product includes an immunity from suit under patents specified in the product insert to use only the amount purchased for the purchaser’s own internal research.  No other patent rights are conveyed expressly, by implication, or by estoppel.  Further information on purchasing licenses may be obtained by contacting the Director of Licensing, Applied Biosystems, 850 Lincoln Centre, Drive, Forest City, CA 94404, USA.

This product is covered by US patent number 6,679,529 B2 owned by Johnson & Boley Holdings, LLC and licensed to GE Healthcare companies.

The NTA ligand is manufactured by QIAGEN GmbH and is under license from F. Hoffmann-La Roche Ltd and QIAGEN GmbH

Notice to purchaser about limited license:
Purchase of this kit includes a limited non-exclusive sublicense under US patent numbers 5,409,811 and 5,498,523. to use the kit to perform one or more patented DNA sequencing methods in those patents solely for use with Sequenase DNA polymerase purchased from GE Healthcare for research activities.  No other license is granted expressly, implied or by estoppel.  For information concerning availability of additional licenses to practice the patented methodologies, contact GE Healthcare Bio-Sciences Corp., 800 Centennial Avenue, P O Box 1327, Piscataway, N.J. 08855-1327, USA.

Sequenase T7 DNA Polymerase is covered by Canadian patents 1335263, 1335962 and 1341512.
Reagent kits for T7 Sequenase DNA Polymerase: This product is covered by or suitable for use under one or more US patent number: 5,409,811 and 5,498,523.

The NTA ligand is manufactured by QIAGEN GmbH and is under license from F. Hoffmann-La Roche Ltd and QIAGEN GmbH

SNuPe is supplied under license from Orchid BioSciences Inc and is covered by US patent numbers 5,888,819, 6,004,744 and equivalent patents and patent applications in other countries.

The purchase price of SNuPe includes a limited, non-transferable license under US patent numbers 5,888,819, 6,004,744 and equivalent patents and patent applications in other countries owned by Orchid BioSciences, Inc. of Princeton, New Jersey, to perform only the number of Genotypes listed on the packaging for this product (For purposes of this End User License, Genotyping means the detection or quantitation of an individual SNP within a single sample.) solely for the detection and analysis of SNPs in samples for research and development purposes, either alone or in a bona fide collaborations with one or more third parties, only and only on an instrument used for gel electrophoretic separation for nucleotide analysis.  This license specifically excludes performing services for a third party and any and all diagnostic or therapeutic uses.  Information about purchasing licenses to practice primer extension technology covered by Orchid BioSciences, Inc. patents for any other use may be obtained by contacting the Senior Director for Business Development at Orchid BioSciences, Inc., Princeton, New Jersey, U.S.A., at (609) 750-2200.

With the purchase of STREAMLINE columns and adsorbents the customer is granted a free license to use the product for the manufacture of biopharmaceutical products under US patent application number 09/250,976 and all US and counterparts in other countries thereof, as well as any patents issuing there from, including US patent number 6,027,650 and equivalent patents and patent applications in other countries. The customer shall not have the right to transfer or sub-license these license rights.

These products are covered by US patent number 6,103,493 and equivalent patents and patent applications in other countries. The purchase of StrepTrap HP and StrepTactin Sepharose High Performance includes a license under such patents for non-profit and in-house research only. Please contact IBA (info@iba-go.com) for further information on licenses for commercial use of StrepTactin.

Purchase of this product includes an immunity from suit under patents specified in the product insert to use only the amount purchased for the purchaser’s own internal research.  No other patent rights are conveyed expressly, by implication, or by estoppel.  Further information on purchasing licenses may be obtained by contacting the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Forest City, California 94404, USA.

Thermo Sequenase DNA Polymerase – this product and/or its method of use is covered by one or more of the following patent numbers: US 5,173,411, US 5,409,811, US 5,498,523 and US 5,614,365 in the name of Harvard and their equivalents in other countries.

Thermo Sequenase I and II are covered by US 5,614,365 owned by the President and Fellows of Harvard College and US 5,885,813 and US 6,479,267 owned by GE Healthcare Bio-Sciences Corp.

This product is sold under a limited use license from Metkinen Chemistry Corporation, and is the subject of one or more of the following patents and patent applications:

“Carbamoylation of amines, thiophenols, mercaptanes and phenols employing organic azides” U.S. Patent Application Serial No. 60/854,721, filed, November 2006.

 Universal Solid Support III is subject to proprietary rights of Glen Research Corporation and synthesized under the following patents, US Patent No.: 6,770,754 and European Patent No.: 1404695.

VIIISelect incorporates BAC BV’s proprietary ligand technology, which has been exclusively licensed to GE Healthcare in the field of purification of beta domain depleted recombinant factor VIII. Other use of this product may require a separate license from BAC BV, Huizerstraatweg 28, 1411 GP Naarden, The Netherlands.

Vistra Green Nucleic Acid Gel Stain is covered by US patent number 5,658,751 and equivalent patents and patent applications in other countries.  The purchase of the product includes a limited non-exclusive sub-license from Molecular Probes Inc to perform the processes set out in this product literature for research purposes only with instrumentation supplied by GE Healthcare. No other license is granted expressly or impliedly.